

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 October 2022 (13.10.2022)



(10) International Publication Number
WO 2022/216723 A1

(51) International Patent Classification:
C07K 16/30 (2006.01)

(21) International Application Number:
PCT/US2022/023501

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:
05 April 2022 (05.04.2022)

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/170,917 05 April 2021 (05.04.2021) US

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **CYTOVIA THERAPEUTICS, LLC.**
[US/US]; 18851 NE 29th Avenue, 2nd Floor, Aventura, Florida 33180 (US).

(72) Inventors: **KADOUCHE, Jean**; c/o Cytovia Therapeutics, Inc., 18851 NE 29th Avenue, 2nd Floor, Aventura, Florida 33180 (US). **LI, Wei**; c/o Cytovia Therapeutics, Inc., 18851 NE 29th Avenue, 2nd Floor, Aventura, Florida 33180 (US). **TEPER, Daniel**; c/o Cytovia Therapeutics, Inc., 18851 NE 29th Avenue, 2nd Floor, Aventura, Florida 33180 (US).


(74) Agent: **ELRIFI, Ivor** et al.; Cooley LLP, 1299 Pennsylvania Ave., NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: BISPECIFIC ANTIBODIES TARGETING NKP46 AND CD38 AND METHODS OF USE THEREOF

FIG. 1A



(57) Abstract: This disclosure provides bispecific antibody molecules that specifically bind to NKP46 and CD38. The disclosure further relates to combination therapies comprising the bispecific antibody molecules. The bispecific antibody molecules can be used to treat, prevent and/or diagnose cancer or infectious conditions or disorders associated with cells expressing NKP46 and/or CD38.

WO 2022/216723 A1